Opvee is a drug owned by Indivior Inc. It is protected by 1 US drug patent filed in 2023 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 10, 2038. Details of Opvee's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11458091 | Compositions and methods for the treatment of opioid overdose |
Jul, 2038
(13 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Opvee's patents.
Latest Legal Activities on Opvee's Patents
Given below is the list of recent legal activities going on the following patents of Opvee.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Post Issue Communication - Certificate of Correction | 13 Jul, 2023 | US11458091 |
| Recordation of Patent Grant Mailed Critical | 04 Oct, 2022 | US11458091 |
| Patent Issue Date Used in PTA Calculation Critical | 04 Oct, 2022 | US11458091 |
| Email Notification Critical | 15 Sep, 2022 | US11458091 |
| Issue Notification Mailed Critical | 14 Sep, 2022 | US11458091 |
| Dispatch to FDC | 08 Sep, 2022 | US11458091 |
| Application Is Considered Ready for Issue Critical | 08 Sep, 2022 | US11458091 |
| Email Notification Critical | 31 Aug, 2022 | US11458091 |
| Mailing Corrected Notice of Allowability | 31 Aug, 2022 | US11458091 |
| Corrected Notice of Allowability | 26 Aug, 2022 | US11458091 |
FDA has granted several exclusivities to Opvee. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Opvee, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Opvee.
Exclusivity Information
Opvee holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2026. Details of Opvee's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 22, 2026 |
US patents provide insights into the exclusivity only within the United States, but Opvee is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Opvee's family patents as well as insights into ongoing legal events on those patents.
Opvee's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Opvee's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jul 10, 2038 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Opvee Generic API suppliers:
Nalmefene Hydrochloride is the generic name for the brand Opvee. 2 different companies have already filed for the generic of Opvee, with Chengdu Shuode having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Opvee's generic
Alternative Brands for Opvee
Opvee which is used for reversing opioid overdose., has several other brand drugs using the same active ingredient (Nalmefene Hydrochloride). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Purdue Pharma Lp |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Nalmefene Hydrochloride, Opvee's active ingredient. Check the complete list of approved generic manufacturers for Opvee
About Opvee
Opvee is a drug owned by Indivior Inc. It is used for reversing opioid overdose. Opvee uses Nalmefene Hydrochloride as an active ingredient. Opvee was launched by Indivior in 2023.
Approval Date:
Opvee was approved by FDA for market use on 22 May, 2023.
Active Ingredient:
Opvee uses Nalmefene Hydrochloride as the active ingredient. Check out other Drugs and Companies using Nalmefene Hydrochloride ingredient
Treatment:
Opvee is used for reversing opioid overdose.
Dosage:
Opvee is available in spray form for nasal use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 2.7MG BASE/SPRAY | SPRAY | Prescription | NASAL |